Cargando…

Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults

This cohort study evaluates the response to a third and fourth SARS-CoV-2 BNT162b2 vaccine dose among individuals aged 60 years or older by evaluating antispike immunoglobulin G antibody titers before and after each dose.

Detalles Bibliográficos
Autores principales:	Eliakim-Raz, Noa, Stemmer, Amos, Ghantous, Nassem, Ness, Asaf, Awwad, Muhammad, Leibovici-Weisman, Yaara, Stemmer, Salomon M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305380/ https://www.ncbi.nlm.nih.gov/pubmed/35862048 http://dx.doi.org/10.1001/jamanetworkopen.2022.23090

Ejemplares similares

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
por: Bar-Haim, Erez, et al.
Publicado: (2022)

Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
por: Eliakim-Raz, Noa, et al.
Publicado: (2021)

Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study
por: Massarweh, Amir, et al.
Publicado: (2022)

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
por: Massarweh, Amir, et al.
Publicado: (2021)

A Transient Inflammatory Reaction with a B-Cell Lymphoid Infiltrate and Dysplastic Bone Marrow Changes Associated with the BNT162b2 COVID-19 Vaccine
por: Vronsky, Daniella, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccination During Pregnancy in Preventing Hospitalization for Severe Acute Respiratory Syndrome Coronavirus 2 in Infants
por: Danino, Dana, et al.
Publicado: (2023)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults
por: Herzberg, Jonas, et al.
Publicado: (2022)

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Magen, Ori, et al.
Publicado: (2022)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
por: Di Noia, Vincenzo, et al.
Publicado: (2022)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

Eight-Month Follow-up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth Dose
por: Lim, Sung Hee, et al.
Publicado: (2023)

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
por: Agbarya, Abed, et al.
Publicado: (2023)

Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
por: Einbinder, Yael, et al.
Publicado: (2022)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients
por: Takazono, Takahiro, et al.
Publicado: (2023)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
por: Stemmer, Amos, et al.
Publicado: (2020)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody titers in healthcare personnel
por: Romero-Ibarguengoitia, Maria Elena, et al.
Publicado: (2022)

Examining the association between vaccine reactogenicity and antibody titer dynamics after the third dose of BNT162b2 vaccine using a mixed-effects model
por: Matsumoto, Naomi, et al.
Publicado: (2023)

The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
por: Amit, Limor, et al.
Publicado: (2013)

Correction: The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
por: Amit, Limor, et al.
Publicado: (2013)

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
por: Assawasaksakul, Theerada, et al.
Publicado: (2022)

Antibody titers against SARS-CoV-2 spike protein 6 months after a third BNT162b2 vaccine in chronic hemodialysis patients
por: El Haggan, Wael, et al.
Publicado: (2022)

1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
por: Debie, Y., et al.
Publicado: (2022)

Six‐months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device‐supported patients
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2022)

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
por: Cohen-Stavi, Chandra J., et al.
Publicado: (2022)

The cost and value of cancer drugs – are new innovations outpacing our ability to pay?
por: Goldstein, Daniel A., et al.
Publicado: (2016)

Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination
por: Kurashima, Kazuyoshi, et al.
Publicado: (2022)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mg9c7kb5t5g8h15ovrc3v7uqoe